Sir, We report here a study that was undertaken to investigate whether ciprofloxacin resistance in Gram-negative nosocomial pathogens is a surrogate marker for cross-resistance to non-fluoroquinolones. The organisms, Escherichia coli (n = 3315), Pseudomonas aeruginosa (n = 1370), Enterobacter aerogenes (n = 252), Enterobacter cloacae (n = 495), Proteus mirabilis (n = 379), Serratia marcescens (n = 207) and Citrobacter freundii (n = 98) were isolated from European hospitals in 1997-1999 as part of the European SENTRY antimicrobial surveillance programme. MICs and breakpoint values of ciprofloxacin, tetracycline, gentamicin, piperacillin, piperacillin/tazobactam, cefuroxime and ceftazidime were determined by broth microdilution according to NCCLS guidelines. 1 The isolates were grouped as either ciprofloxacin susceptible or resistant, and the number and percentage of organisms resistant to the antimicrobials are shown in Table 1 . The statistical significance of cross-resistance was calculated by Fisher's exact test and was corrected using the Bonferroni-Holm procedure.
Ciprofloxacin resistance was most prevalent in E. aerogenes, with 27% of isolates resistant, followed by P. aeruginosa with 24%. E. cloacae and S. marcescens had the lowest incidence of ciprofloxacin resistance, at 5% and 7%, respectively. Amongst the ciprofloxacin-susceptible isolates, piperacillin/tazobactam was the most potent agent, with resistance rates of 0-9%. Piperacillin on its own was less potent with resistance levels of up to 38%. Ciprofloxacinresistant P. aeruginosa and E. cloacae isolates show more than a six-and three-fold increase in piperacillin resistance, and a seven-fold rise in resistance levels to piperacillin/ tazobactam (P < 0.01). The other organisms showed a two-to four-fold increase in resistance to these agents, and S. marcescens exhibited a seven-fold increase in resistance to piperacillin. Ciprofloxacin-resistant P. mirabilis remained 100% susceptible to piperacillin/tazobactam. Gentamicin resistance was also relatively low in the ciprofloxacinsusceptible group, with resistance rates of 1.6-7.1%. These rates increased two-to 14-fold in the ciprofloxacin-resistant group, with E. coli showing the largest increase.
Tetracycline resistance rates increased 16-fold for ciprofloxacin-resistant E. aerogenes (P < 0.05); for the other organisms this increase was a more modest four-fold or less. P. mirabilis isolates are almost universally resistant to tetracycline. Nearly all P. aeruginosa isolates were cefuroxime resistant, irrespective of ciprofloxacin resistance. For the other organisms, cefuroxime resistance levels were less than or equal to seven-fold higher if ciprofloxacin resistant, and S. marcescens was 100% resistant. A similar trend was seen with ceftazidime: a two-to nine-fold increase in resistance associated with ciprofloxacin resistance. Imipenem was tested against P. aeruginosa and resistance levels were six-fold higher in the ciprofloxacin-resistant population (P < 0.01). No significant cross-resistance was seen with C. freundii.
These data show that the relationship between ciprofloxacin resistance and resistance to unrelated drugs was statistically significant. There exist interspecies differences on the effects of ciprofloxacin resistance, for example gentamicin/ciprofloxacin resistance in E. aerogenes is not statistically significant compared with E. coli (P < 0.001). However, ciprofloxacin resistance can be used as a general surrogate marker of multidrug resistance.
The resistance mechanisms of the isolates were not investigated in this study, nor was the relatedness of isolates within a species; therefore, the process by which an organism goes from susceptible to multidrug resistant is open to speculation. Ciprofloxacin resistance probably followed multidrug resistance, given that resistance levels are low in the ciprofloxacinsusceptible group. Indeed, ciprofloxacin therapy might have been used when other therapeutic options were compromised because of resistance. However, ciprofloxacin therapy has been shown to select for multidrug resistance by causing Another route to multidrug resistance is mediated through the acquisition and dissemination of resistance determinants. These resistance genes are found on integrons and are disseminated through transposons and plasmids. Genes encoding resistance to extended-spectrum β-lactams, aminoglycosides, chloramphenicol, co-trimoxazole, streptomycin, sulfamethoxazole and quaternary ammonium compounds have all been found on integrons in the Enterobacteriaceae. Leverstein-Van Hall et al. 4 found integrons with resistance genes against drugs that had been used rarely, if ever, in the past 20 years, indicating the persistence and stability of these genes without selective pressure. Jones et al. 5 found that integrons carrying aminoglycoside-modifying enzymes are widespread throughout Europe. Transfer of resistance from a Klebsiella donor to an E. coli recipient showed that the integron was on a plasmid. Martinez-Freijo et al. 6 found that integron-positive isolates were statistically more likely to be multidrug resistant than integron-negative isolates. Leverstein-Van Hall et al. 4 also showed that integrons are associated with multidrug-resistant Enterobacteriaceae. These were found to be involved in horizontal transfer, as the same integrons were found on different species that had colonized patients. These integrons were transferred experimentally at high frequency.
